In summary, atRA not only enhanced the anti-leukemic effects of sorafenib on AML blasts with an FLT3-ITD mutation, but also reduced the frequency of LSCs both by itself and together with sorafenib. This evidence concerns the gene FLT3 and acute myeloid leukemia.